From: Treating critically ill patients with probiotics: Beneficial or dangerous?
Study | Study design | Number of patients | Probiotics/Synbiotics | Results |
---|---|---|---|---|
Jain et al. [11] | double-blind, randomized, placebo-control. | 90 ICU patients: 45 verum vs 45 placebo. | 4 × 109 of Lact. acidophilus, Bifid. lactis, L. bulgaricus, Strept. thermophilus + 7,5 g Oligofructose. | less potentially pathogenic bact. no differences: septic outcome mortality, ICU stay. |
McNaught et al. [12] | nonblinded, randomized, nonplacebo. | 103 critical lll: 51 verum vs 52 placebo. | L. plantarum 299v + oatmeal + fruit drink. | no differences: intestinal permeability, CRP level morbidity + mortality. |
Olah et al. [13] | double-blind, randomized, placebo-control. | 62 patients with acute pancreatitis: 29 vs 33. | Synbiotic 2000 Forte. | no differences: mortality, septic complications, organ failure. |
Barraud et al. [14] | double-blind, randomized, placebo-control. | 167 ICU patients: 84 verum vs 83 placebo. | 2 × 1010 Lact. rhamnosus GG. | no differences: mortality, ICU acquired infections. |